Mesoblast/$MESO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mesoblast
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Ticker
$MESO
Sector
Trading on
Industry
Biotechnology
Headquarters
Melbourne, Australia
Employees
73
ISIN
US5907174016
Website
Mesoblast Metrics
BasicAdvanced
$1.4B
-
-$0.09
2.13
-
Price and volume
Market cap
$1.4B
Beta
2.13
52-week high
$22.00
52-week low
$5.78
Average daily volume
201K
Financial strength
Current ratio
0.958
Quick ratio
0.563
Long term debt to equity
23.029
Total debt to equity
27.34
Interest coverage (TTM)
-2.43%
Management effectiveness
Return on assets (TTM)
-4.85%
Return on equity (TTM)
-21.31%
Valuation
Price to revenue (TTM)
2,110.255
Price to book
4.16
Price to tangible book (TTM)
-16.89
Price to free cash flow (TTM)
-279.691
Growth
Revenue change (TTM)
-24.07%
Earnings per share change (TTM)
7.13%
3-year revenue growth (CAGR)
-16.86%
3-year earnings per share growth (CAGR)
-15.43%
What the Analysts think about Mesoblast
Analyst ratings (Buy, Hold, Sell) for Mesoblast stock.
Mesoblast Financial Performance
Revenues and expenses
Mesoblast Earnings Performance
Company profitability
Mesoblast News
AllArticlesVideos
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
GlobeNewsWire·2 weeks ago
Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials
Seeking Alpha·4 weeks ago
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mesoblast stock?
Mesoblast (MESO) has a market cap of $1.4B as of May 30, 2025.
What is the P/E ratio for Mesoblast stock?
The price to earnings (P/E) ratio for Mesoblast (MESO) stock is 0 as of May 30, 2025.
Does Mesoblast stock pay dividends?
No, Mesoblast (MESO) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Mesoblast dividend payment date?
Mesoblast (MESO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mesoblast?
Mesoblast (MESO) has a beta rating of 2.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.